Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH, June 15 (Reuters) - Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. The Swiss drugmaker said Zessly, its Remicade biosimilar, matched the original medicine for safety and efficacy at 54 weeks, including in patients who switched from the original. Switching from